Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia - PubMed
3 hours ago
- #STAR-T cells
- #AML therapy
- #LILRB4 targeting
- LILRB4 is targeted by STAR-T cell therapy as a promising antigen for AML due to its high expression on monocytic AML cells and absence on hematopoietic stem cells.
- Dual epitope anti-LILRB4 STAR-T cells demonstrate superior tumor inhibition compared to single epitope STAR-T or dual epitope CAR-T cells in preclinical models.
- A clinical trial with 9 relapsed/refractory AML patients showed a best overall response rate of 50%, with manageable safety including no severe neurotoxicity or cytokine release syndrome.
- Treatment failures may be linked to monocyte-mediated suppression of T-cell function, identified through single-cell RNA sequencing in nonresponders.